<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the time-action profiles and the dose-response relationship of the long-acting insulin analogues insulin detemir (IDet) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>) in type 2 diabetic patients belonging to different ethnic groups </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Forty-eight type 2 diabetic patients belonging to different ethnic groups (three groups of 16 African Americans (AA), 16 Hispanics/Latinos (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) and 16 Caucasians) participated in this double-blind crossover trial </plain></SENT>
<SENT sid="2" pm="."><plain>Each patient took part in six 16-h isoglycaemic <z:chebi fb="105" ids="17234">glucose</z:chebi> clamps (clamp target 7.2 mmol/l) and was randomly allocated to three doses (0.3, 0.6 and 1.2 (I)U/kg) of IDet and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: IDet and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> showed comparable pharmacodynamic effects [the area under the <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion rate curve (AUC(GIR 0-16 h)) (mg/kg)] in the investigated dose range: IDet, 0.3 U/kg, 207 AA, 535 HL, 285 Caucasians; 0.6 U/kg, 1203 AA, 824 HL and 1126 Caucasians; 1.2 U/kg, 1502 AA, 1977 HL and 2269 Caucasians; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>, 0.3 IU/kg, 733 AA, 1148 HL and 1148 Caucasians; 0.6 IU/kg, 1395 AA, 1976 HL and 1077 Caucasians; 1.2 IU/kg, 2452 AA, 3296 HL and 2455 Caucasians </plain></SENT>
<SENT sid="4" pm="."><plain>Both IDet and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> showed a linear dose-response relationship in <z:hpo ids='HP_0000001'>all</z:hpo> three groups (p = 0.31), without any significant differences in slope (p = 0.71) or intercept (p = 0.51) </plain></SENT>
<SENT sid="5" pm="."><plain>Comparable results were obtained for pharmacokinetics </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: These results confirm a linear dose-response relationship of IDet, without any relevant differences between ethnic groups </plain></SENT>
<SENT sid="7" pm="."><plain>This suggests that similar dosing recommendation can be used for IDet in type 2 diabetic patients belonging to different ethnic group </plain></SENT>
</text></document>